| 000 | 01303 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250514022856.0 | ||
| 264 | 0 | _c20020220 | |
| 008 | 200202s 0 0 spa d | ||
| 022 | _a0036-3634 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBarrón-González, A | |
| 245 | 0 | 0 |
_a[Antiestrogens: mechanism of action and clinical applications]. _h[electronic resource] |
| 260 |
_bSalud publica de Mexico _c |
||
| 300 |
_a577-84 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; English Abstract; Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents, Hormonal _xtherapeutic use |
| 650 | 0 | 4 |
_aBreast Neoplasms _xprevention & control |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 |
_aEstrogen Antagonists _xtherapeutic use |
| 650 | 0 | 4 |
_aEstrogen Receptor Modulators _xpharmacology |
| 650 | 0 | 4 |
_aEstrogens _xphysiology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aModels, Theoretical |
| 650 | 0 | 4 | _aPostmenopause |
| 650 | 0 | 4 |
_aRaloxifene Hydrochloride _xtherapeutic use |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aTamoxifen _xanalogs & derivatives |
| 650 | 0 | 4 |
_aToremifene _xtherapeutic use |
| 700 | 1 | _aArias-Martínez, J | |
| 700 | 1 | _aCastro-Romero, I | |
| 773 | 0 |
_tSalud publica de Mexico _gvol. 43 _gno. 6 _gp. 577-84 |
|
| 999 |
_c11726142 _d11726142 |
||